NCT07315282

Brief Summary

The study will be a randomized, double-blind, 17-day metabolic intervention trial including 14 days of high-dose or low-dose iron supplementation. A total of 70 overweight or obese (OW/OB) women will be enrolled. Participants will be individually randomized into either the high-iron or low-iron group. Women in the low-iron group will receive 15 mg of iron as ferrous fumarate daily for 14 days, while women in the high-iron group will receive 195 mg of iron as ferrous sulfate daily for 14 days. The study consists of three visits in total. On Day 0, a fasting blood sample will be collected and an OGTT will be performed, with additional blood samples collected at 1 hour and 2 hours post-OGTT. The OGTT will be repeated on Day 14, after 14 days of oral iron supplementation, and again on Day 17, four days after oral iron supplementation has been stopped

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
1mo left

Started Dec 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Dec 2025Jun 2026

First Submitted

Initial submission to the registry

December 18, 2025

Completed
5 days until next milestone

Study Start

First participant enrolled

December 23, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 2, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Last Updated

January 2, 2026

Status Verified

December 1, 2025

Enrollment Period

6 months

First QC Date

December 18, 2025

Last Update Submit

December 18, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Blood glucose increase during OGTT Day 0

    Blood glucose increase during OGTT before the intake of oral iron for 14 days

    Day 0

  • Blood glucose increase during OGTT Day 14

    Blood glucose increase during OGTT after the intake of oral iron for 14 days

    Day 14

Secondary Outcomes (33)

  • Insulin increase during OGTT Day 0

    Day 0

  • Insulin increase during OGTT Day 14

    Day 14

  • Serum Hepcidin Day 0

    Day 0

  • Serum Hepcidin D14

    Day 14

  • Serum Ferritin Day 0

    Day 0

  • +28 more secondary outcomes

Study Arms (2)

high-dose iron supplementation

EXPERIMENTAL

195 mg iron as ferrous sulfate daily for 14 days

Dietary Supplement: 195 mg iron daily

low-dose iron supplementation

ACTIVE COMPARATOR

15 mg iron as ferrous fumarate daily for 14 days

Dietary Supplement: 15 mg iron daily

Interventions

195 mg iron dailyDIETARY_SUPPLEMENT

3 x 65 mg iron as ferrous sulfate

high-dose iron supplementation
15 mg iron dailyDIETARY_SUPPLEMENT

3 x 5 mg iron as ferrous sulfate

low-dose iron supplementation

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • BMI ≥ 27.5 kg/m2
  • serum ferritin \<30 μg/L
  • hemoglobin ≥ 11 g/dl
  • fasting blood glucose \< 5.6 mmol/L

You may not qualify if:

  • intravenous or high dose oral iron in the preceding 2 months
  • medical disorders are known to affect iron absorption or metabolism, or T2DM
  • cigarette smoking
  • recent blood transfusion or major blood loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

American University of Beirut

Beirut, Lebanon

RECRUITING

MeSH Terms

Conditions

Overweight

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

December 18, 2025

First Posted

January 2, 2026

Study Start

December 23, 2025

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Last Updated

January 2, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations